{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:18:23Z","timestamp":1768263503608,"version":"3.49.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":1464,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/bja\/aet401","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:38:33Z","timestamp":1386895113000},"page":"i96-i113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"S1","title":["New oral anticoagulants and regional anaesthesia"],"prefix":"10.1016","volume":"111","author":[{"given":"H.T.","family":"Benzon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Avram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.O.","family":"Bonow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/bja\/aet401_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/AAP.0b013e3181c15c70","article-title":"Regional anesthesia in the patient receiving antithrombotic therapy or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition)","volume":"35","author":"Horlocker","year":"2010","journal-title":"Reg Anesth Pain Med"},{"key":"10.1093\/bja\/aet401_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/EJA.0b013e32833f6f6f","article-title":"Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology","volume":"27","author":"Gogarten","year":"2010","journal-title":"Eur J Anaesthesiol"},{"key":"10.1093\/bja\/aet401_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1399-6576.2009.02089.x","article-title":"Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine","volume":"54","author":"Breivik","year":"2010","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1093\/bja\/aet401_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2141.2010.08094.x","article-title":"Managing anticoagulated patients during neuraxial anaesthesia","volume":"149","author":"Green","year":"2010","journal-title":"Br J Hematol"},{"key":"10.1093\/bja\/aet401_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/ALN.0b013e3181ebdb15","article-title":"Novel oral anticoagulants: implications in the perioperative setting","volume":"113","author":"Levy","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1093\/bja\/aet401_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1213\/ANE.0b013e318203f38d","article-title":"Antiplatelet drugs: a review of their pharmacology and management in the perioperative period","volume":"112","author":"Hall","year":"2011","journal-title":"Anesth Analg"},{"issue":"Suppl. 1","key":"10.1093\/bja\/aet401_bib7","doi-asserted-by":"crossref","first-page":"i96","DOI":"10.1093\/bja\/aer381","article-title":"Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy","volume":"107","author":"Horlocker","year":"2011","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib8","doi-asserted-by":"crossref","first-page":"e3675","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"Gomez-Outez","year":"2012","journal-title":"Br Med J"},{"key":"10.1093\/bja\/aet401_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/EJA.0b013e32835f4d5b","article-title":"Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology","volume":"30","author":"Kozek-Langenecker","year":"2013","journal-title":"Eur J Anaesthesiol"},{"key":"10.1093\/bja\/aet401_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Hemostasis and the French Study Group on Thrombosis and Haemostasis","volume":"104","author":"Sie","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1093\/bja\/aet401_bib11","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/ALN.0b013e318289bcba","article-title":"Managing new oral anticoagulants in the perioperative and intensive care unit setting","volume":"118","author":"Levy","year":"2013","journal-title":"Anesthesiology"},{"key":"10.1093\/bja\/aet401_bib12","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMra1206531","article-title":"Management of antithrombotic therapy in patients undergoing invasive procedures","volume":"368","author":"Baron","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11239-013-0911-2","article-title":"Practical issues, limitations, and periprocedural management of the NOAC\u2019s","volume":"36","author":"Connolly","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1093\/bja\/aet401_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-013-0963-5","article-title":"Perioperative management of patients who are receiving a novel oral anticoagulant","volume":"8","author":"Liew","year":"2013","journal-title":"Intern Emerg Med"},{"key":"10.1093\/bja\/aet401_bib15","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2012-12-453076","article-title":"The laboratory and the direct oral anticoagulants","volume":"121","author":"Tripodi","year":"2013","journal-title":"Blood"},{"key":"10.1093\/bja\/aet401_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jth.12096","article-title":"Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants","volume":"11","author":"Garcia","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-013-0885-0","article-title":"Reversal of novel oral anticoagulants in patients with major bleeding","volume":"35","author":"Siegal","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1093\/bja\/aet401_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1093\/bja\/aet401_bib19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1345\/aph.1R724","article-title":"Current state of knowledge on oral anticoagulant reversal using procoagulant factors","volume":"47","author":"Nitzki-George","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"Suppl. 1","key":"10.1093\/bja\/aet401_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jth.12227","article-title":"The role of the laboratory in treatment with new oral anticoagulants","volume":"11","author":"Baglin","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJMe1107516","article-title":"New options in anticoagulation for atrial fibrillation","volume":"365","author":"del Zoppo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH11-12-0827","article-title":"The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the multicenter BNK Online bRiDging Registry (BORDER)","volume":"108","author":"Omran","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"issue":"2 Suppl.","key":"10.1093\/bja\/aet401_bib24","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1378\/chest.11-2298","article-title":"American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"Suppl. 1","key":"10.1093\/bja\/aet401_bib25","first-page":"77","article-title":"Perioperative management of long-term anticoagulation","volume":"24","author":"Kearon","year":"1998","journal-title":"Semin Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.STR.12.6.879","article-title":"Complications of lumbar puncture followed by anticoagulation","volume":"12","author":"Ruff","year":"1981","journal-title":"Stroke"},{"key":"10.1093\/bja\/aet401_bib27","first-page":"303","article-title":"Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia","volume":"80","author":"Horlocker","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1093\/bja\/aet401_bib28","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/00000539-200212000-00041","article-title":"Risk assessment of hemorrhagic complications associated with nonsteroidal anti-inflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection","volume":"95","author":"Horlocker","year":"2002","journal-title":"Anesth Analg"},{"key":"10.1093\/bja\/aet401_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/rapm-00115550-198409020-00008","article-title":"Bleeding time and nerve blocks in patients who had aspirin","volume":"9","author":"Benzon","year":"1984","journal-title":"Reg Anesth"},{"key":"10.1093\/bja\/aet401_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bja\/69.1.109","article-title":"Aspirin, extradural anaesthesia and the MRC Collaborative Low-dose Aspirin Study in Pregnancy","volume":"69","author":"de Swiet","year":"1992","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00115550-199823062-00006","article-title":"Neuraxial anesthesia and analgesia in the presence of standard heparin","volume":"23","author":"Liu","year":"1998","journal-title":"Reg Anesth Pain Med"},{"key":"10.1093\/bja\/aet401_bib32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1365-2044.2007.05195.x","article-title":"Selected new antithrombotic agents and neuraxial anaesthesia for major orthopedic surgery: management strategies","volume":"62","author":"Rosencher","year":"2007","journal-title":"Anaesthesia"},{"issue":"Suppl.)","key":"10.1093\/bja\/aet401_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1093\/bja\/aet401_bib34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/ALN.0b013e3181ca6cfc","article-title":"Factor VII levels and risk factors for increased international normalized ratio in the early phase of warfarin therapy","volume":"112","author":"Benzon","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1093\/bja\/aet401_bib35","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/bja\/aer298","article-title":"Determination of the residual antiplatelet activity of clopidogrel","volume":"107","author":"Benzon","year":"2011","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.me.36.020185.002225","article-title":"Elimination half-life of drugs: value and limitations","volume":"36","author":"Greenblatt","year":"1985","journal-title":"Ann Rev Med"},{"key":"10.1093\/bja\/aet401_bib37","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1056\/NEJMe1012149","article-title":"Therapeutic potential of oral factor Xa inhibitors","volume":"363","author":"Hylek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-2007-982083","article-title":"Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor","volume":"33","author":"Laux","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1093\/bja\/aet401_bib39","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"Br Med J"},{"key":"10.1093\/bja\/aet401_bib40","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1213\/00000539-199412000-00024","article-title":"Anticoagulants and spinal-epidural anesthesia","volume":"79","author":"Vandermeulen","year":"1994","journal-title":"Anesth Analg"},{"key":"10.1093\/bja\/aet401_bib41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/rapm-00115550-199318040-00014","article-title":"When to remove a spinal or epidural catheter in an anticoagulated patient","volume":"18","author":"Horlocker","year":"1993","journal-title":"Reg Anesth"},{"key":"10.1093\/bja\/aet401_bib42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07853890600852898","article-title":"Thrombin activates fibrinolysis inhibitor (TAF)\u2014how does thrombin regulate fibrinolysis?","volume":"38","author":"Bouma","year":"2006","journal-title":"Ann Med"},{"key":"10.1093\/bja\/aet401_bib43","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomized trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/bja\/aet401_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ana.23744","article-title":"Advanced imaging to extend the therapeutic window of ischemic stroke","volume":"73","author":"Fisher","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1093\/bja\/aet401_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.thromres.2008.01.018","article-title":"Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage","volume":"123","author":"Tertri","year":"2008","journal-title":"Thromb Res"},{"key":"10.1093\/bja\/aet401_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1365-2125.2012.04285.x","article-title":"Bioactivity of enoxaparin in critically ill patients with normal renal function","volume":"74","author":"Gouya","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib48","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Disposition"},{"key":"10.1093\/bja\/aet401_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development","volume":"48","author":"Ericksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/bja\/aet401_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 1","key":"10.1093\/bja\/aet401_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1093\/bja\/aet401_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/bja\/aet401_bib53","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1093\/bja\/aet401_bib54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. An open label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/bja\/aet401_bib56","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1093\/bja\/aet401_bib57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11239-009-0409-0","article-title":"New oral anticoagulants: a practical guide to clinicians","volume":"29","author":"Wittkowsky","year":"2010","journal-title":"J Thromb Thrombolysis"},{"key":"10.1093\/bja\/aet401_bib58","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib59","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib60","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran versus placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1093\/bja\/aet401_bib61","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.arth.2009.08.010","article-title":"Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with safety profile comparable to placebo","volume":"25","author":"Fuji","year":"2010","journal-title":"J Arthroplasty"},{"key":"10.1093\/bja\/aet401_bib62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Ericksson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib63","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Ericksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial","volume":"370","author":"Ericksson","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/bja\/aet401_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1093\/bja\/aet401_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1160\/TH08-07-0493","article-title":"Efficacy and safety of dabigatran etaxilate for the prevention of venous thromboembolism following hip or knee arthroplasty. A meta-analysis","volume":"101","author":"Wolowacz","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib67","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1538-7836.2004.00890.x","article-title":"Dose escalating safety study of a new direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I","volume":"2","author":"Ericksson","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib68","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1213\/ANE.0b013e318251daed","article-title":"The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the multicenter perioperative outcomes group research consortium","volume":"116","author":"Bateman","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1093\/bja\/aet401_bib69","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"Harper","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1093\/bja\/aet401_bib70","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib71","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib72","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","article-title":"Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient","volume":"69","author":"Miyares","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1093\/bja\/aet401_bib73","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib74","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1093\/bja\/aet401_bib75","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/bja\/aes501","article-title":"Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P\/N): a pharmacovigilance study","volume":"110","author":"Hanke","year":"2013","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib76","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1093\/bja\/aet401_bib77","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib78","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1160\/TH09-03-0196","article-title":"Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014in elderly Chinese subjects","volume":"103","author":"Jiang","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib79","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1093\/bja\/aet401_bib80","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs","volume":"141S","author":"Weitz","year":"2012","journal-title":"Chest"},{"key":"10.1093\/bja\/aet401_bib81","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib83","unstructured":"Rivaroxaban Package Insert, Janssen Pharmaceuticals, Titusville, NJ."},{"key":"10.1093\/bja\/aet401_bib84","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939)\u2014an oral, direct factor Xa inhibitor\u2014has no clinically relevant interaction with naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib85","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/jth.12033","article-title":"Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis","volume":"10","author":"Becker","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib86","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib87","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe1112770","article-title":"A new era in secondary prevention after coronary artery syndrome","volume":"366","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib90","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib91","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib92","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/bja\/aet401_bib93","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib94","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1093\/bja\/aet401_bib95","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Ericksson","year":"2009","journal-title":"J Bone Joint Surg Br"},{"key":"10.1093\/bja\/aet401_bib96","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/aas.12069","article-title":"Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs enoxaparin)","volume":"57","author":"Rosencher","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1093\/bja\/aet401_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban\u2014an oral direct factor Xa inhibitor\u2014in patients undergoing major orthopedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/bja\/aet401_bib98","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/jth.12165","article-title":"Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay","volume":"11","author":"Samama","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib99","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/bja\/aet401_bib100","first-page":"476","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy sbjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1093\/bja\/aet401_bib101","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib102","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1124\/dmd.108.025981","article-title":"Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/bja\/aet401_bib103","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug\u2013drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/bja\/aet401_bib104","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.12114","article-title":"Extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with anitiplatelet therapy after coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib106","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib107","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib108","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib109","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib110","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patient with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib111","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJMe1109748","article-title":"A new era for anticoagulation in atrial fibrillation","volume":"365","author":"Mega","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib112","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib113","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib114","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/bja\/aet401_bib115","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib116","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J Throm Haemost"},{"key":"10.1093\/bja\/aet401_bib117","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11239-011-0591-8","article-title":"Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban\u2014an oral, direct and selective factor Xa inhibitor","volume":"32","author":"Becker","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1093\/bja\/aet401_bib118","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib119","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12265-013-9458-z","article-title":"Platelet function testing and tailored antiplatelet therapy","volume":"6","author":"Janssen","year":"2013","journal-title":"J Cardiovasc Trans Res"},{"key":"10.1093\/bja\/aet401_bib120","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jacc.2012.11.080","article-title":"Platelet function tests in clinical cardiology","volume":"61","author":"Gorog","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/bja\/aet401_bib121","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1093\/bja\/aet401_bib122","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jth.12219","article-title":"Antiplatelet therapy: new pharmacological agents and changing paradigms","volume":"11","author":"Capodanno","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib123","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1093\/bja\/aet401_bib124","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1592\/phco.29.9.1089","article-title":"Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor","volume":"29","author":"Dobesh","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1093\/bja\/aet401_bib125","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1124\/dmd.106.014522","article-title":"The disposition of prasugrel, a novel thienopyridine, in humans","volume":"35","author":"Farid","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/bja\/aet401_bib126","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11630740-000000000-00000","article-title":"Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications","volume":"51","author":"Floyd","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/bja\/aet401_bib127","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/09537100600565551","article-title":"Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans","volume":"17","author":"Asai","year":"2006","journal-title":"Platelets"},{"key":"10.1093\/bja\/aet401_bib128","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1093\/bja\/aet401_bib129","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/bja\/aet401_bib130","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMp0806848","article-title":"Prasugrel in clinical practice","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib131","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FJC.0b013e3181492209","article-title":"Increased active metabolite explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel","volume":"50","author":"Payne","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1093\/bja\/aet401_bib132","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2710.2009.01068.x","article-title":"Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease","volume":"34","author":"Small","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1093\/bja\/aet401_bib133","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2710.2009.01067.x","article-title":"Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease","volume":"34","author":"Small","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1093\/bja\/aet401_bib134","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1093\/bja\/aet401_bib135","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1093\/bja\/aet401_bib136","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2125.2011.04049.x","article-title":"Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants","volume":"73","author":"Kelly","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib137","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib138","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1093\/bja\/aet401_bib139","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib140","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects","volume":"66","author":"Teng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib141","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/bja\/aet401_bib142","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1093\/bja\/aet401_bib143","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0091270010379409","article-title":"Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment","volume":"51","author":"Butler","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1093\/bja\/aet401_bib144","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.amjcard.2008.07.038","article-title":"Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin+thienopyridine) following drug eluting stent implantation","volume":"102","author":"Latib","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1093\/bja\/aet401_bib145","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1093\/bja\/aet401_bib146","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/bja\/aer288","article-title":"Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures","volume":"107","author":"Collyer","year":"2011","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib147","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.athoracsur.2005.01.009","article-title":"Comparison of two strategies for the management of antiplatelet therapy during urgent surgery","volume":"80","author":"Akowuah","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1093\/bja\/aet401_bib148","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1213\/ane.0b013e3181731e95","article-title":"Coronary stents II. Perioperative considerations and management","volume":"107","author":"Newsome","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1093\/bja\/aet401_bib149","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(00)02175-9","article-title":"Platelets","volume":"355","author":"George","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/bja\/aet401_bib150","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"van Giezen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib151","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.hoc.2013.03.003","article-title":"Testing platelet function","volume":"27","author":"Harrison","year":"2013","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1093\/bja\/aet401_bib152","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/09537104.2011.601361","article-title":"Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant","volume":"23","author":"Edwards","year":"2012","journal-title":"Platelets"},{"key":"10.1093\/bja\/aet401_bib153","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/09537104.2012.689037","article-title":"Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance","volume":"23","author":"Tsantes","year":"2012","journal-title":"Platelets"},{"key":"10.1093\/bja\/aet401_bib154","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1538-7836.2009.03733.x","article-title":"Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel","volume":"8","author":"Bouman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib155","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1160\/TH09-11-0803","article-title":"Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel","volume":"104","author":"Berge","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib156","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","article-title":"Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention","volume":"24","author":"Gaglia","year":"2011","journal-title":"J Interv Cardiol"},{"key":"10.1093\/bja\/aet401_bib157","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/1076029608322547","article-title":"Utility of the PFA-100 insturment and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease","volume":"15","author":"Mueller","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1093\/bja\/aet401_bib158","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1160\/TH09-02-0126","article-title":"Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2)","volume":"102","author":"Blais","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib159","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/09537100802657735","article-title":"Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM","volume":"20","author":"Scharbert","year":"2009","journal-title":"Platelets"},{"key":"10.1093\/bja\/aet401_bib160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/bja\/aep184","article-title":"Thrombelastography platelet mapping is a useful preoperative tool in surgical patients taking antiplatelet medication (letter)","volume":"103","author":"Kaur","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib161","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bja\/aep039","article-title":"Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography\u00ae Platelet Mapping\u2122","volume":"102","author":"Collyer","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1093\/bja\/aet401_bib162","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/09537100701280654","article-title":"Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100)","volume":"18","author":"Dyszkiewicz-Korpanty","year":"2007","journal-title":"Platelets"},{"key":"10.1093\/bja\/aet401_bib163","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/09537100802317918","article-title":"The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence","volume":"19","author":"van Werkum","year":"2008","journal-title":"Platelets"},{"key":"10.1093\/bja\/aet401_bib164","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/bja\/aet401_bib165","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/bja\/aet401_bib166","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1093\/bja\/aet401_bib167","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00101-005-0827-0","article-title":"Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine","volume":"54","author":"Kozek-Langenecker","year":"2005","journal-title":"Anaesthesist"},{"key":"10.1093\/bja\/aet401_bib168","doi-asserted-by":"crossref","DOI":"10.3109\/02688697.2013.793289","article-title":"Spinal epidural haematoma; factors influencing outcome","author":"Mukerji","year":"2013","journal-title":"Br J Neurosurg"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091217309340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091217309340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bja\/article-pdf\/111\/suppl_1\/i96\/619908\/aet401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T18:33:44Z","timestamp":1757788424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091217309340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":168,"alternative-id":["S0007091217309340"],"URL":"https:\/\/doi.org\/10.1093\/bja\/aet401","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New oral anticoagulants and regional anaesthesia","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/bja\/aet401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Author(s). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}